Abstract: Accordingly, certain embodiments of the invention provide a conjugate of formula (I): P-(X-D)n, wherein P is a peptide that binds to a glucose regulated protein 78 (GRP78); X is a direct bond or a linking group; D is a detectable agent; and n is 1 to 4. Certain embodiments of the invention provide a pharmaceutical composition comprising a conjugate of formula (I) and a pharmaceutically acceptable excipient. Certain embodiments of the invention provide a method for treating or preventing cancer in an animal (e.g., a human) comprising administering a therapeutically effective amount of a conjugate of formula (I) (e.g., a conjugate comprising a therapeutic radionuclide) to the animal.

Abstract: This application discloses the method for separating element or isotopes such as protactinium and gallium and isotopes thereof from a corresponding mixture which method comprises contacting the mixture with a carbon-based separation material, wherein the carbon-based separation material selectively associates with the element or isotope thereof.

Abstract: The invention provides a method to treat cancer in an animal comprising administering a tetra-arylethylene cation to the animal.

Abstract: This disclosure provides radiolabeled compounds that bind to guanylyl cyclase C (GCC) and which can bind cancer cells that express GCC. Exemplary compounds comprise a chelating moiety capable of binding a radioactive atom, a peptide capable of binding GCC, and a linker moiety connecting the two. This disclosure also provides methods of detecting and treating cancer using the compounds described herein.

Abstract: The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.

Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.

Abstract: The present invention relates to aptamer conjugates comprising a metal chelating group and to methods of using these aptamers.